A venture arm of a large company is a stage-agnostic investor, and makes investments from Series B to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $5-10 million with the possibility of follow-on investments up to $20 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.
The firm focuses on four areas of innovation in healthcare; pharma services, data and analytics, digital supply chain, consumer health, value based care. The firm is focused on financial returns in addition to how the firm can potentially contribute value to the company.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply